Z Gastroenterol 2005; 43 - 99
DOI: 10.1055/s-2005-869746

Functional overtalk between the capsaicin-sensitive afferent and efferent vagal nerve during gastric mucosal protection produced by omeprazole and omeprazole-like compounds

Zs Peidl 1, A Dömötör 1, O Karádi 1, Gy Szekeres 4, K Hideg 2, J Szolcsányi 3, Gy Mózsik 1
  • 11st Dept. of Med.
  • 2Inst. of Organic and Med. Chemistry, Med. and Health Center
  • 3Dept. of Pharmacology and Pharmacotherapy
  • 4Univ. of Pécs, Histopathology Ltd., Pécs, Hungary

Aims: The drugs acting of the efferent nerves for mucosal prevention (against different exogenous and endogenous agents). Omeprazole is a prototype of proton pump inhibitors (PPI), while the omeprazole-like compounds have antiischaemic and poly (ADP-ribose) polymerase (PARP) inhibitor properties.

Aims: was to receive different immunohistochemical evidences for the existence of functional cross-talk between the efferent and capsaicin-sensitive afferent vagal nerve, when the gastric mucosal protection was produced by the drugs acting on the efferent vagal nerves.

Materials and methods: The observations were carried out in CFY-strain rats (180–210g), fasted 24h. After pylorus ligation or IND-treatment (20mg/kg sc.), omeprazole (5 or 10mg/kg b.w., sc., ED50 value of Omeprazole=5mg/kg) and omeprazole-like compounds (L-2279, L-2243, HO-3215, HO-3098, HO-3243; 5 or 10mg/kg b.w., sc.) were administered. The animals were sacrificed 4h after the treatments. We measured the gastric acid secretion (4h after pylorus-ligation), the number and severity of gastric ulcers, the immundistribution of CR1, CGRP and SP. The immunostaining of these antigens were evaluated in formalin-fixed, paraffin-embedded gastric tissue sections of the rats using mono- and polyclonal antibodies (Abcam, Cambrige, UK).

Results: 1. All of the compounds inhibited dose-dependently the gastric acid secretion and mucosal damage; 2. The expression of CR1, CGRP and SP decreased significantly is both in pylorus-ligated and indomethacin-treated animals; 3. The expression of CR1 and CGRP turned back meanwhile no damage was obtained in SP expression during the gastric mucosal protection produced by omeprazole and omeprazole-like compounds.

Conclusion: The omeprazole-like compounds (together with antiischaemic and poly (ADP-ribose) polymerase (PARP) inhibitor properties prevent the gastric acid secretion and gastric mucosal damage.